Enlonstobart

DRUG6 trials

Sponsors

Shanghai JMT-Bio Inc., CSPC Megalith Biopharmaceutical Co.,Ltd., Shanghai Chest Hospital, Fudan University

Conditions

Advanced Solid TumorsHER2-positive Gastric CancerNon-Small Cell Lung CancerNon-small Cell Lung CancerRectal Cancer

Phase 1

SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors

Not yet recruitingNCT07622225

CSPC Megalith Biopharmaceutical Co.,Ltd.Advanced Solid Tumors

Start: 2026-05-29End: 2030-01-31Target: 264Updated: 2026-06-03

Phase 2

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Not yet recruitingNCT06998771

Shanghai JMT-Bio Inc.HER2-positive Gastric Cancer

Start: 2025-06-15End: 2029-12-31Target: 153Updated: 2025-05-31

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not yet recruitingNCT07332533

Shanghai JMT-Bio Inc.HER2-positive Gastric Cancer

Start: 2025-12-30End: 2032-12-31Target: 490Updated: 2026-01-12

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

Not yet recruitingNCT07662811

Shanghai Chest HospitalNon-Small Cell Lung Cancer

Start: 2026-06-01End: 2029-12-31Target: 396Updated: 2026-06-29

Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer

Not yet recruitingNCT07810114

Fudan UniversityRectal Cancer

Start: 2026-08-28End: 2030-12-01Target: 52Updated: 2026-09-09

Phase 3

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

Not yet recruitingNCT07672223

CSPC Megalith Biopharmaceutical Co.,Ltd.Non-small Cell Lung Cancer

Start: 2026-06-25End: 2031-11-30Target: 570Updated: 2026-06-26